(S)-(1-FMOC-哌啶-2-基)乙酸 | 193693-62-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 芴
• 中文名称: (S)-(1-FMOC-哌啶-2-基)乙酸
• 中文别名: (S)-(1-Fmoc-哌啶-2-基)-乙酸
• 英文名称: (S)-(1-Fmoc-piperidin-2-yl)-acetic acid
• 英文别名: (S)-Fmoc-(2-carboxymethyl)-piperidine；(S)-2-(1-(((9H-Fluoren-9-yl)methoxy)carbonyl)piperidin-2-yl)acetic acid；2-[(2S)-1-(9H-fluoren-9-ylmethoxycarbonyl)piperidin-2-yl]acetic acid
• CAS: 193693-62-8
• 化学式: C₂₂H₂₃NO₄
• 分子量: 365.429
• InChiKey: YVHXTQQJFAOBCJ-HNNXBMFYSA-N

物化性质

• 沸点：
  575.0±23.0 °C(Predicted)
• 密度：
  1.252±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  27
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  66.8
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335

反应信息

• 作为反应物：
  描述：

  Fmoc-L-天冬氨酸 beta-叔丁酯 、 4-guanidinocinnamic acid hydrochloride 、 (S)-(1-FMOC-哌啶-2-基)乙酸 、 alkaline earth salt of/the/ methylsulfuric acid 生成 (S)-2-[(S)-3-Carboxy-2-(2-{(S)-1-[(E)-3-(4-guanidino-phenyl)-acryloyl]-piperidin-2-yl}-acetylamino)-propionylamino]-3-methyl-butyric acid
  参考文献：
  名称：

  Constrained β-alanine based GpIIb/IIIa antagonists

  摘要：

  The concepts of centrally constrained and peptide based fibrinogen receptor antagonists have been successfully combined into a single series of analogs which have been demonstrated to be potent inhibitors of platelet aggregation. (C) 1997 Elsevier Science Ltd.

  DOI：

  10.1016/s0960-894x(97)00311-9

文献信息

• Peptides comprising non-natural amino acids and methods of making and using the same
  申请人：Longevity Biotech, Inc.

  公开号：US10543255B2

  公开（公告）日：2020-01-28

  This invention relates to novel compositions comprising analogs of naturally occurring polypeptides, wherein the analog comprises an α-amino acid and at least one β-amino acid. Administration of the compositions may be used for effecting treatment or prevention of a plurality of disease states caused by dysfunctional biochemical or biological pathways. The compositions and methods of this invention are particularly useful to identify novel therapeutic modulators of in-vivo receptor activity with extended half-lives and relevant bioactivity as compared to the naturally translated polypeptides upon which the analogs are derived.

  本发明涉及由天然多肽类似物组成的新型组合物，其中类似物包括一种α-氨基酸和至少一种β-氨基酸。给药组合物可用于治疗或预防由生化或生物途径功能障碍引起的多种疾病状态。本发明的组合物和方法特别适用于鉴定体内受体活性的新型治疗调节剂，与天然翻译的多肽相比，本发明的类似物具有更长的半衰期和相关的生物活性。
• Highly active polypeptides and methods of making and using the same
  申请人：Longevity Biotech, Inc.

  公开号：US10772934B2

  公开（公告）日：2020-09-15

  This invention relates to novel compositions comprising analogs of naturally occurring polypeptides, wherein the analog comprises an α-amino acid and at least one β-amino acid. Administration of the compositions may be used for effecting treatment or prevention of a plurality of disease states caused by dysfunctional biochemical or biological pathways. The compositions and methods of this invention are particularly useful to identify novel therapeutic modulators of in-vivo receptor activity with extended half-lives and relevant bioactivity as compared to the naturally translated polypeptides upon which the analogs are derived.

  本发明涉及由天然多肽类似物组成的新型组合物，其中类似物包括一种α-氨基酸和至少一种β-氨基酸。给药组合物可用于治疗或预防由生化或生物途径功能障碍引起的多种疾病状态。本发明的组合物和方法特别适用于鉴定体内受体活性的新型治疗调节剂，与天然翻译的多肽相比，本发明的类似物具有更长的半衰期和相关的生物活性。
• EP2694095A1
  申请人：——

  公开号：EP2694095A1

  公开（公告）日：2014-02-12
• COMPOSITIONS COMPRISING GLUCAGON ANALOGS AND METHODS OF MAKING AND USING THE SAME
  申请人：Longevity Biotech, Inc.

  公开号：EP2694095B1

  公开（公告）日：2018-03-07
• PEPTIDES COMPRISING NON-NATURAL AMINO ACIDS AND METHODS OF MAKING AND USING THE SAME
  申请人：Longevity Biotech, Inc.

  公开号：EP2968469A2

  公开（公告）日：2016-01-20